Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:49:42 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:SLS from 2023-04-30 to 2024-04-29 - 43 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-29 08:45U:SLSNews ReleaseSELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
2024-03-28 16:05U:SLSNews ReleaseSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
2024-03-26 07:35U:SLSNews ReleaseSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
2024-03-19 16:05U:SLSNews ReleaseSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
2024-03-19 08:47U:SLSNews ReleaseSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
2024-03-15 09:01U:SLSNews ReleaseSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
2024-03-08 08:00U:SLSNews ReleaseSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
2024-03-01 08:30U:SLSNews ReleaseSELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
2024-02-29 08:01U:SLSNews ReleaseSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
2024-02-06 08:30U:SLSNews ReleaseSELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
2024-01-25 08:45U:SLSNews ReleaseSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
2024-01-09 08:30U:SLSNews ReleaseSELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
2024-01-04 09:02U:SLSNews ReleaseSELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
2024-01-03 20:05U:SLSNews ReleaseSELLAS Life Sciences Announces Proposed Public Offering
2024-01-03 07:30U:SLSNews ReleaseSELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
2023-12-27 08:55U:SLSNews ReleaseSELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo ‚ ® in Advanced Malignant Pleural Mesothelioma
2023-12-21 08:15U:SLSNews ReleaseSELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
2023-12-14 08:30U:SLSNews ReleaseSELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
2023-12-13 08:30U:SLSNews ReleaseSELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
2023-12-04 08:47U:SLSNews ReleaseSELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia
2023-11-29 08:45U:SLSNews ReleaseSELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
2023-11-13 08:50U:SLSNews ReleaseSELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)
2023-11-09 16:05U:SLSNews ReleaseSELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-11-06 08:57U:SLSNews ReleaseSELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda ‚ ® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society
2023-10-31 08:05U:SLSNews ReleaseSELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-10-30 09:03U:SLSNews ReleaseSELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
2023-10-17 08:45U:SLSNews ReleaseSELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda ‚ ® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual
2023-10-16 08:45U:SLSNews ReleaseSELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia
2023-10-12 16:05U:SLSNews ReleaseSELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia
2023-10-11 08:30U:SLSNews ReleaseSELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas
2023-10-10 16:16U:SLSNews ReleaseSELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia
2023-09-21 08:30U:SLSNews ReleaseSELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
2023-09-18 16:19U:SLSNews ReleaseSELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference
2023-08-22 08:30U:SLSNews ReleaseSELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications
2023-08-10 16:09U:SLSNews ReleaseSELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-06-28 08:30U:SLSNews ReleaseSELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo ‚ ® in Advanced Malignant Pleural Mesothelioma
2023-06-22 08:45U:SLSNews ReleaseSELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia
2023-06-15 16:05U:SLSNews ReleaseSELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting
2023-06-13 08:30U:SLSNews ReleaseSELLAS to Participate in Maxim Group Healthcare Virtual Conference
2023-05-25 17:05U:SLSNews ReleaseSELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting
2023-05-16 08:30U:SLSNews ReleaseSELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia
2023-05-11 16:12U:SLSNews ReleaseSELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
2023-05-04 08:30U:SLSNews ReleaseSELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study